Cassava sciences inc (SAVA)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-1,150

-1,516

-697

-1,059

-1,359

-677

-1,267

-2,453

-2,160

-2,418

-2,590

-4,160

-2,743

-2,522

-3,518

-3,015

-5,795

-4,517

-3,671

-3,374

-2,583

-2,156

-3,535

-3,245

-3,450

33,015

-762

-301

-408

-1,794

-1,551

-131

30

-391

-815

-1,200

-207

Adjustments to reconcile net loss to net cash used in operating activities:
Deferred program fee revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35,244

1,958

1,959

1,958

2,468

2,725

2,724

2,724

2,724

2,725

2,724

2,724

Non-cash stock-based compensation

270

304

319

329

344

403

484

699

802

750

687

709

827

845

845

934

1,710

818

795

882

962

1,004

1,090

884

783

771

839

812

679

2,577

2,257

869

907

1,211

1,491

1,423

1,303

Depreciation and amortization

14

-

14

13

17

-

18

17

17

-

17

16

18

-

13

14

14

-

14

14

4

-

3

4

3

-

-

-

-

-

52

35

35

35

35

40

53

Gain on sale of property and equipment

100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash net interest income

-

-

-

-

-

-

-

-

-

0

0

0

2

5

0

0

3

-

-

-

-

-

-

-

-

1

1

1

7

3

-75

-137

-133

-168

-287

-300

-386

Changes in operating assets and liabilities:
Other current assets

9

-129

336

-91

-93

-43

246

-82

-72

-104

276

-114

-230

-104

341

-184

-139

-194

320

81

-120

-119

-124

341

-124

-124

386

-124

-126

-125

283

-380

117

274

0

5,118

-5,178

Other non-current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-86

0

11

Accounts payable

155

113

-254

99

201

-255

-413

541

-3

-288

54

93

270

-760

705

-665

9

116

433

210

82

-649

462

-68

-17

-86

96

69

5

-146

6

-1

38

-92

-48

168

-671

Accrued development expense

-390

362

236

-64

87

156

0

-18

-381

399

-32

24

-19

-717

103

-177

-76

252

194

241

182

-312

5

31

-340

-101

170

190

-547

136

188

186

-495

160

178

141

177

Accrued compensation and benefits

14

3

-5

-2

1

-

-

-

-

11

-11

7

-33

-5

-594

-549

860

-423

146

162

86

-572

177

168

167

162

171

-735

261

-224

700

-709

171

130

153

-868

-212

Other current liabilities

2

2

-7

2

12

-

-4

2

10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10

7

-

0

0

-24

0

-17

7

-48

-14

-14

16

-3

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,787

-3,274

-3,142

-3,548

-2,410

-1,948

-1,147

-2,563

-1,672

-2,591

-2,723

-1,454

-1,819

-1,801

-1,873

-

-

-

-

-

-

-

-

Net cash used in operating activities

-1,194

-589

-730

-591

-604

-565

-1,436

-1,126

-1,643

-1,437

-2,151

-3,197

-1,452

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,297

-1,950

-2,070

-

-1,173

-1,547

3,269

Cash flows from investing activities:
Purchases of property and equipment

-

0

0

0

18

-

-

-

-

-

-

-

-

-1

76

0

0

0

0

0

195

1

0

0

79

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

100

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

0

0

0

399

2,095

549

0

1,497

0

899

949

1,999

-2

1,101

249

1,250

1,249

1,299

1,299

2,797

6,892

4,286

4,795

4,795

-

-

-

-

Sales of marketable securities

-

-

-

-

-

-

-

-

-

0

0

0

400

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

0

0

0

2,100

-

-

-

-

-

-

-

-

1,100

250

1,250

1,250

1,300

1,300

2,800

6,900

4,287

14,803

11,800

7,500

5,000

10,000

4,998

42,402

Net cash provided (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-625

1,500

-1,497

900

51

1,051

-2,194

1,101

-851

1,001

-79

51

1

1,501

4,103

-

-

-

-

-

-

-

-

Net cash provided by / (used in) investing activities

100

0

0

0

-18

-

-

-

-

0

0

0

2,101

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,517

7,005

2,705

-

10,000

4,998

42,402

Cash flows from financing activities:
Issuance costs from 2018 sale of common stock and warrants

-

0

0

0

60

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of common stock and warrants, net

-

-

-

-

-

-72

12,272

0

1,898

-

-

-

-

-

-

-

-

-

-

-

-

0

0

313

66

264

0

254

6

-

-

-

-

80

52

4,485

4,425

Proceeds from exercise of common stock warrants, net

3,613

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs

-

-

-

-

-

-

-

-

-

-

-

-

-

24

0

0

46

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-214

-46

-

-

-

-

0

0

313

66

264

0

254

6

-

-

-

-

-

-

-

-

Net cash provided by / (used in) financing activities

3,613

5,866

0

0

-60

-72

12,272

0

1,898

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

52

4,485

4,425

Net increase / (decrease) in cash and cash equivalents

2,519

5,277

-730

-591

-682

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) / increase in cash and cash equivalents

-

-

-

-

-

-

-

-

255

-1,437

-2,151

-3,197

649

-4,599

-3,412

-1,988

-4,685

-2,694

-2,359

-897

-3,341

-1,462

-2,523

-1,277

-2,736

-1,139

-1,818

-46

2,236

-38,885

9,220

5,241

635

1,435

8,879

7,936

50,096